INTELLECTUAL PROPERTY

Intellectual Property—18 Issued or Allowed Patents

Glycotest IP strategy is to enable multiple layers of protection for key liver disease tests through multiple patent families prosecuted in commercially important jurisdictions—individual biomarkers; assay technology; panels and algorithms

HCC Panel patent application (PCT/US2017/018040 and Taiwan 106106107)

  • Panels and algorithms, including the HCC Panel
  • Protection to 2037, including in China

PCT/US2010/044307

  • Engineered lectins and methods for fucosylated biomarker assays
  • Issued European (2462240) and Chinese (ZL201080044720.8) patents
  • Protection to 2030, including in China

PCT/US2006/017478

  • Methods for diagnosing liver disease using fucosylated biomarkers
  • Issued US (7,776,550; 8,183,000; 10,082,512; 10,823,740), European (3056905), Australian (2006244398; 2012247075; 2015275300), Japanese (5964769; 6184935; 6553142), Canadian (2607285), Hong Kong (HK1228005), and additional allowed European patent
  • Protection to 2026

US2009/0253180

  • Methods for diagnosing liver disease using fucosylated LRAGG
  • Issued US patents (9,110,078; 10,180,436)
  • Protection to 2028

Trade Secrets

  • Fucosylated biomarker assay manufacturing technology
  • Fucosylated biomarker assay methods

KEY FEATURES

- Exploits unique disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individuals

- Incorporated into highly promising biomarker panels

- Focused on the detection of potentially curable early-stage disease

- May outperform currently available serum biomarkers, such as AFP

- Targeting the worldwide liver cancer threat that kills more than 700,000 people annually and is the fastest growing cause of cancer death in the US

GLYCOTEST PRESENTATION

A New Paradigm for Early Diagnosis and Surveillance For Liver Cancer

GLYCOTEST TECHNOLOGY

Glycotest blood tests are being developed to provide information on the likelihood of serious liver disease like cancer or fibrosis-cirrhosis by employing technology designed to measure two kinds of disease signals:

» The amount of the monosaccharide fucose that appears abnormally on certain serum glycoproteins—to indicate likelihood of disease.

» The pattern of glycoproteins that is abnormally fucosylated—to monitor specific diseases like HCC, CCA or fibrosis-cirrhosis.

Intellectual Property | Glycotest Diagnostics